Pharmacogenomics in pediatric oncology: Australian adolescent or young adult and caregiver perspectives

Preemptive pharmacogenomic (PGx) testing in pediatric oncology patients could reduce toxicity and improve efficacy of medications yet remains underutilized. Consumer identified implementation barriers have not been extensively explored nor included adolescent or young adult (AYA) patient perspectives. This study describes Australian pediatric oncology consumer perspectives on PGx testing, elucidating barriers to implementation.

Citation:
Moore C, Magavern EF, Alexander M, ……. Kotecha RS, Mateos MK, et al. Pharmacogenomics in pediatric oncology: Australian adolescent or young adult and caregiver perspectives. Genetics in Medicine Open. 2025;3.

Keywords:
Adolescents; Caregivers; Oncology; Pharmacogenetics; Young adult

Abstract:
Preemptive pharmacogenomic (PGx) testing in pediatric oncology patients could reduce toxicity and improve efficacy of medications yet remains underutilized. Consumer identified implementation barriers have not been extensively explored nor included adolescent or young adult (AYA) patient perspectives. This study describes Australian pediatric oncology consumer perspectives on PGx testing, elucidating barriers to implementation.